glp-1 drugs review The New Evolution of GLP‐1 Receptor Agonists

Current Opinion in Rheumatology

1 Introduction Obstructive sleep apnea syndrome (OSAS) is a chronic sleep-related breathing disorder characterized by recurrent upper airway collapse during sleep, leading to intermittent hypoxemia, sleep architecture disruption, and impaired daytime functioning (1, 2)

doi: 10.1016/j.neuropharm.2019.107748

Contrastingly, GLP1 antagonist sales in 2023 showcase a more diversified landscape, with therapeutics such as Ozempic, Trulicity, and Mounjaro driving 71 per cent of the sales. Looking ahead, the GLP1 agonist market is poised for robust growth, anticipating a 19.2 per cent compound annual growth rate (CAGR) from 2023 to 2029, reaching a substantial market size of $105 billion in 2029

Semaglutide, another GLP-1 analog, has also shown efficacy in MASH (see semaglutide for MASH)